Literature DB >> 1514170

Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits.

M O Palmier1, L J Hall, C M Reisch, M K Baldwin, A G Wilson, T C Wun.   

Abstract

The pharmacokinetics of recombinant tissue factor pathway inhibitor (TFPI) after an intravenous bolus injection was studied in rabbits. Clearance of TFPI was followed by measurement of the radioactivity of the 125I-labelled compound in the whole plasma or the trichloroacetic acid precipitate and by quantitation of the functional TFPI activity of the unlabelled compound using a tissue factor-induced coagulation assay. When iodinated TFPI was used, the ratios of the trichloroacetic acid precipitable counts vs. that of the whole plasma was about 1 in the first 10 min after TFPI injection, but this ratio gradually decreased to less than 0.5 after 2 h. This result suggested that the iodinated TFPI in the plasma was partially degraded after prolonged circulation in the animal. When unlabelled TFPI was used, the clearance of TFPI activity from the plasma exhibited bi-exponential elimination kinetics with a rapid alpha phase half-life (t1/2 alpha) of 2.3 min, and a terminal beta phase half-life (t1/2 beta) of 79 min. The plasma clearance was 4.2 ml kg-1 min-1. The tissue distribution of intravenously administered 125I-TFPI in the rabbit was studied using whole-body autoradiography. At 3 min after dosing, significant levels of TFPI were apparent in the liver, kidney, and other highly blood perfused tissues. Significant levels of 125I-TFPI-derived radioactivity were also apparent in the liver and kidney at 30 min after intravenous administration. The localization within the liver demonstrated a mottled appearance, suggesting regions of higher uptake within the liver. In the kidney, the outer cortex consistently revealed the highest activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1514170

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Tissue factor pathway inhibitor in childhood nephrotic syndrome.

Authors:  Mohamed M Al-Mugeiren; Abdel Galil M Abdel Gader; Saud A Al-Rasheed; Abdullah A Al-Salloum
Journal:  Pediatr Nephrol       Date:  2006-03-31       Impact factor: 3.714

2.  Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor.

Authors:  A E Mast; D A Higuchi; Z F Huang; I Warshawsky; A L Schwartz; G J Broze
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

3.  Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

Authors:  J H Erlich; J Apostolopoulos; T C Wun; K K Kretzmer; S R Holdsworth; P G Tipping
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2.

Authors:  Makoto Motoyoshi; Masanori Sugiyama; Yutaka Atomi; Wataru Kimura; Hirokazu Nagawa
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

5.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis.

Authors:  Hao-Lan He; Ji-Bin Zhang; Qian Li
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

Authors:  I Warshawsky; G J Broze; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Authors:  A A Creasey; A C Chang; L Feigen; T C Wün; F B Taylor; L B Hinshaw
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 9.  Tissue factor pathway inhibitor: structure-function.

Authors:  George J Broze; Thomas J Girard
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 10.  A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.

Authors:  Aline R M Lobba; Miryam Paola Alvarez-Flores; Melissa Regina Fessel; Marcus Vinicius Buri; Douglas S Oliveira; Renata N Gomes; Priscila S Cunegundes; Carlos DeOcesano-Pereira; Victor D Cinel; Ana M Chudzinski-Tavassi
Journal:  Front Mol Biosci       Date:  2022-08-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.